Adding Oncolytic Virus to Immunotherapy for Advanced Melanoma is Found to be Cost Prohibitive (CME/CE)
(MedPage Today) -- Combination treatment does not extend life and has little clinical benefit, cost-analysis finds
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Immunotherapy | International Medicine & Public Health | Melanoma | Skin Cancer